STAT+: Pharmalittle: Glaxo under more pressure from activist investor; WHO urges Gilead to lower price of black-fungus drug
Hello, everyone, and how are you today? A shiny sun and delightful breeze are enveloping the Pharmalot campus this morning, where things have quieted down now that the short person has left for gainful employment and the official mascot is out and about. As for us, we are staring at the intimidating to-do list and quaffing cups of stimulation. Perhaps you can relate? In any event, we have once again assembled a few items of interest to get you started on your day. So here you go. Hope you conquer the world and keep us in mind when you run across something intriguing. …
Elliott Management intensified pressure on GlaxoSmithKline (GSK) and called for the drug maker to replace board members and launch a process to decide whether chief executive officer Emma Walmsley should continue to lead the group, The Wall Street Journal tells us. In a 17-page letter to Glaxo chairman Jonathan Symonds, the hedge fund argued Glaxo has a poor record of execution, its share price has underperformed for years, and its management lacked credibility.
